A mitochondria-targeted fatty acid analogue influences hepatic glucose metabolism and reduces the plasma insulin/glucose ratio in male Wistar rats


Autoři: Carine Lindquist aff001;  Bodil Bjørndal aff001;  Hege G. Bakke aff003;  Grete Slettom aff002;  Marie Karoliussen aff003;  Arild C. Rustan aff003;  G. Hege Thoresen aff003;  Jon Skorve aff001;  Ottar K. Nygård aff001;  Rolf Kristian Berge aff001
Působiště autorů: Department of Clinical Science, University of Bergen, Bergen, Norway aff001;  Department of Heart Disease, Haukeland University Hospital, Bergen, Norway aff002;  Section for Pharmacology and Pharmaceutical Biosciences, Department of Pharmacy, University of Oslo, Oslo, Norway aff003;  Department of Pharmacology, Institute of Clinical Medicine, University of Oslo, Oslo, Norway aff004
Vyšlo v časopise: PLoS ONE 14(9)
Kategorie: Research Article
doi: 10.1371/journal.pone.0222558

Souhrn

A fatty acid analogue, 2-(tridec-12-yn-1-ylthio)acetic acid (1-triple TTA), was previously shown to have hypolipidemic effects in rats by targeting mitochondrial activity predominantly in liver. This study aimed to determine if 1-triple TTA could influence carbohydrate metabolism. Male Wistar rats were treated for three weeks with oral supplementation of 100 mg/kg body weight 1-triple TTA. Blood glucose and insulin levels, and liver carbohydrate metabolism gene expression and enzyme activities were determined. In addition, human myotubes and Huh7 liver cells were treated with 1-triple TTA, and glucose and fatty acid oxidation were determined. The level of plasma insulin was significantly reduced in 1-triple TTA-treated rats, resulting in a 32% reduction in the insulin/glucose ratio. The hepatic glucose and glycogen levels were lowered by 22% and 49%, respectively, compared to control. This was accompanied by lower hepatic gene expression of phosphenolpyruvate carboxykinase, the rate-limiting enzyme in gluconeogenesis, and Hnf4A, a regulator of gluconeogenesis. Gene expression of pyruvate kinase, catalysing the final step of glycolysis, was also reduced by 1-triple TTA. In addition, pyruvate dehydrogenase activity was reduced, accompanied by 10-15-fold increased gene expression of its regulator pyruvate dehydrogenase kinase 4 compared to control, suggesting reduced entry of pyruvate into the TCA cycle. Indeed, the NADPH-generating enzyme malic enzyme 1 (ME1) catalysing production of pyruvate from malate, was increased 13-fold at the gene expression level. Despite the decreased glycogen level, genes involved in glycogen synthesis were not affected in livers of 1-triple TTA treated rats. In contrast, the pentose phosphate pathway seemed to be increased as the hepatic gene expression of glucose-6-phosphate dehydrogenase (G6PD) was higher in 1-triple TTA treated rats compared to controls. In human Huh7 liver cells, but not in myotubes, 1-triple-TTA reduced glucose oxidation and induced fatty acid oxidation, in line with previous observations of increased hepatic mitochondrial palmitoyl-CoA oxidation in rats. Importantly, this work recognizes the liver as an important organ in glucose homeostasis. The mitochondrially targeted fatty acid analogue 1-triple TTA seemed to lower hepatic glucose and glycogen levels by inhibition of gluconeogenesis. This was also linked to a reduction in glucose oxidation accompanied by reduced PHD activity and stimulation of ME1 and G6PD, favouring a shift from glucose- to fatty acid oxidation. The reduced plasma insulin/glucose ratio indicate that 1-triple TTA may improve glucose tolerance in rats.

Klíčová slova:

Fatty acids – Gene expression – Glucose – Glycogens – Insulin – Mitochondria – Oxidation – Pyruvate


Zdroje

1. Berge RK, Tronstad KJ, Berge K, Rost TH, Wergedahl H, Gudbrandsen OA, et al (2005) The metabolic syndrome and the hepatic fatty acid drainage hypothesis. Biochimie. 87(1):15–20. doi: 10.1016/j.biochi.2004.11.011 15733731

2. Lindquist C, Bjorndal B, Rossmann CR, Tusubira D, Svardal A, Rosland GV, et al (2017) Increased hepatic mitochondrial FA oxidation reduces plasma and liver TG levels and is associated with regulation of UCPs and APOC-III in rats. Journal of Lipid Research. 58(7):1362–1373. doi: 10.1194/jlr.M074849 28473603

3. Saltiel AR, Kahn CR (2001) Insulin signalling and the regulation of glucose and lipid metabolism. Nature. 414(6865):799–806. doi: 10.1038/414799a 11742412

4. Consoli A (1992) Role of liver in pathophysiology of NIDDM. Diabetes Care. 15(3):430–441. doi: 10.2337/diacare.15.3.430 1559410

5. Stark R, Guebre-Egziabher F, Zhao X, Feriod C, Dong J, Alves TC, et al (2014) A role for mitochondrial phosphoenolpyruvate carboxykinase (PEPCK-M) in the regulation of hepatic gluconeogenesis. J Biol Chem. 289(11):7257–7263. doi: 10.1074/jbc.C113.544759 24497630

6. Pilkis SJ, Granner DK (1992) Molecular physiology of the regulation of hepatic gluconeogenesis and glycolysis. Annu Rev Physiol. 54 885–909. doi: 10.1146/annurev.ph.54.030192.004321 1562196

7. Zhang S, Hulver MW, McMillan RP, Cline MA, Gilbert ER (2014) The pivotal role of pyruvate dehydrogenase kinases in metabolic flexibility. Nutr Metab (Lond). 11(1):10. doi: 10.1186/1743-7075-11-10 24520982

8. Buse MG (2006) Hexosamines, insulin resistance, and the complications of diabetes: current status. Am J Physiol Endocrinol Metab. 290(1):E1–E8. doi: 10.1152/ajpendo.00329.2005 16339923

9. Schleicher ED, Weigert C (2000) Role of the hexosamine biosynthetic pathway in diabetic nephropathy. Kidney Int Suppl. 77 S13–18. 10997685

10. Barcia-Vieitez R, Ramos-Martinez JI (2014) The regulation of the oxidative phase of the pentose phosphate pathway: new answers to old problems. IUBMB Life. 66(11):775–779. doi: 10.1002/iub.1329 25408203

11. Shulman GI, Rothman DL, Jue T, Stein P, DeFronzo RA, Shulman RG (1990) Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy. N Engl J Med. 322(4):223–228. doi: 10.1056/NEJM199001253220403 2403659

12. Tomiyasu M, Obata T, Nishi Y, Nakamoto H, Nonaka H, Takayama Y, et al (2010) Monitoring of liver glycogen synthesis in diabetic patients using carbon-13 MR spectroscopy. Eur J Radiol. 73(2):300–304. doi: 10.1016/j.ejrad.2008.10.019 19058940

13. Harper P, Wadstrom C, Cederblad G (1993) Carnitine measurements in liver, muscle tissue, and blood in normal subjects. Clin Chem. 39(4):592–599. 8472351

14. Reuter SE, Evans AM, Chace DH, Fornasini G (2008) Determination of the reference range of endogenous plasma carnitines in healthy adults. Ann Clin Biochem. 45(Pt 6):585–592. doi: 10.1258/acb.2008.008045 18782814

15. Reuter SE, Evans AM, Faull RJ, Chace DH, Fornasini G (2005) Impact of haemodialysis on individual endogenous plasma acylcarnitine concentrations in end-stage renal disease. Ann Clin Biochem. 42(Pt 5):387–393. doi: 10.1258/0004563054889954 16168195

16. Urbaniak G, Plous S: Research Randomizer. In, 2013.

17. Berge RK, Flatmark T, Osmundsen H (1984) Enhancement of long-chain acyl-CoA hydrolase activity in peroxisomes and mitochondria of rat liver by peroxisomal proliferators. Eur J Biochem. 141(3):637–644. doi: 10.1111/j.1432-1033.1984.tb08239.x 6146524

18. Willumsen N, Hexeberg S, Skorve J, Lundquist M, Berge RK (1993) Docosahexaenoic acid shows no triglyceride-lowering effects but increases the peroxisomal fatty acid oxidation in liver of rats. J Lipid Res. 34(1):13–22. 8445337

19. Henry RR, Abrams L, Nikoulina S, Ciaraldi TP (1995) Insulin action and glucose metabolism in nondiabetic control and NIDDM subjects. Comparison using human skeletal muscle cell cultures. Diabetes. 44(8):936–946. doi: 10.2337/diab.44.8.936 7622000

20. Gaster M, Beck-Nielsen H, Schroder HD (2001) Proliferation conditions for human satellite cells. The fractional content of satellite cells. APMIS. 109(11):726–734. doi: 10.1034/j.1600-0463.2001.d01-139.x 11900051

21. Gaster M, Kristensen SR, Beck-Nielsen H, Schroder HD (2001) A cellular model system of differentiated human myotubes. APMIS. 109(11):735–744. doi: 10.1034/j.1600-0463.2001.d01-140.x 11900052

22. Wensaas AJ, Rustan AC, Lovstedt K, Kull B, Wikstrom S, Drevon CA, et al (2007) Cell-based multiwell assays for the detection of substrate accumulation and oxidation. J Lipid Res. 48(4):961–967. doi: 10.1194/jlr.D600047-JLR200 17213484

23. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 72 248–254. doi: 10.1006/abio.1976.9999 942051

24. Hessvik NP, Bakke SS, Fredriksson K, Boekschoten MV, Fjorkenstad A, Koster G, et al (2010) Metabolic switching of human myotubes is improved by n-3 fatty acids. J Lipid Res. 51(8):2090–2104. doi: 10.1194/jlr.M003319 20363834

25. Chavalit T, Rojvirat P, Muangsawat S, Jitrapakdee S (2013) Hepatocyte nuclear factor 4alpha regulates the expression of the murine pyruvate carboxylase gene through the HNF4-specific binding motif in its proximal promoter. Biochim Biophys Acta. 1829(10):987–999. doi: 10.1016/j.bbagrm.2013.05.001 23665043

26. Xu HF, Luo J, Zhao WS, Yang YC, Tian HB, Shi HB, et al (2016) Overexpression of SREBP1 (sterol regulatory element binding protein 1) promotes de novo fatty acid synthesis and triacylglycerol accumulation in goat mammary epithelial cells. J Dairy Sci. 99(1):783–795. doi: 10.3168/jds.2015-9736 26601584

27. Iizuka K (2017) The Role of Carbohydrate Response Element Binding Protein in Intestinal and Hepatic Fructose Metabolism. Nutrients. 9(2). doi: 10.3390/nu9020181 28241431

28. Morral N (2003) Novel targets and therapeutic strategies for type 2 diabetes. Trends Endocrinol Metab. 14(4):169–175. 12714277

29. Chakravarty K, Cassuto H, Reshef L, Hanson RW (2005) Factors that control the tissue-specific transcription of the gene for phosphoenolpyruvate carboxykinase-C. Crit Rev Biochem Mol Biol. 40(3):129–154. doi: 10.1080/10409230590935479 15917397

30. Mosseri R, Waner T, Shefi M, Shafrir E, Meyerovitch J (2000) Gluconeogenesis in non-obese diabetic (NOD) mice: in vivo effects of vandadate treatment on hepatic glucose-6-phoshatase and phosphoenolpyruvate carboxykinase. Metabolism. 49(3):321–325. doi: 10.1016/s0026-0495(00)90132-x 10726908

31. Stark R, Kibbey RG (2014) The mitochondrial isoform of phosphoenolpyruvate carboxykinase (PEPCK-M) and glucose homeostasis: has it been overlooked? Biochim Biophys Acta. 1840(4):1313–1330. doi: 10.1016/j.bbagen.2013.10.033 24177027

32. Jeoung NH, Wu P, Joshi MA, Jaskiewicz J, Bock CB, Depaoli-Roach AA, et al (2006) Role of pyruvate dehydrogenase kinase isoenzyme 4 (PDHK4) in glucose homoeostasis during starvation. Biochem J. 397(3):417–425. doi: 10.1042/BJ20060125 16606348

33. Muna ZA, Bolann BJ, Chen X, Songstad J, Berge RK (2000) Tetradecylthioacetic acid and tetradecylselenoacetic acid inhibit lipid peroxidation and interact with superoxide radical. Free Radic Biol Med. 28(7):1068–1078. doi: 10.1016/s0891-5849(00)00196-9 10832068

34. Muna ZA, Gudbrandsen OA, Wergedahl H, Bohov P, Skorve J, Berge RK (2002) Inhibition of rat lipoprotein oxidation after tetradecylthioacetic acid feeding. Biochem Pharmacol. 63(6):1127–1135. doi: 10.1016/s0006-2952(01)00934-0 11931845

35. Bjorndal B, Grimstad T, Cacabelos D, Nylund K, Aasprong OG, Omdal R, et al (2013) Tetradecylthioacetic Acid Attenuates Inflammation and Has Antioxidative Potential During Experimental Colitis in Rats. Digestive Diseases and Sciences. 58(1):97–106. doi: 10.1007/s10620-012-2321-2 22855292

36. Vigerust NF, Cacabelos D, Burri L, Berge K, Wergedahl H, Christensen B, et al (2012) Fish oil and 3-thia fatty acid have additive effects on lipid metabolism but antagonistic effects on oxidative damage when fed to rats for 50 weeks. J Nutr Biochem. 23(11):1384–1393. doi: 10.1016/j.jnutbio.2011.08.006 22221672


Článek vyšel v časopise

PLOS One


2019 Číslo 9

Nejčtenější v tomto čísle

Tomuto tématu se dále věnují…


Kurzy

Zvyšte si kvalifikaci online z pohodlí domova

Léčba bolesti v ordinaci praktického lékaře
nový kurz
Autoři: MUDr. PhDr. Zdeňka Nováková, Ph.D.

Revmatoidní artritida: včas a k cíli
Autoři: MUDr. Heřman Mann

Jistoty a nástrahy antikoagulační léčby aneb kardiolog - neurolog - farmakolog - nefrolog - právník diskutují
Autoři: doc. MUDr. Štěpán Havránek, Ph.D., prof. MUDr. Roman Herzig, Ph.D., doc. MUDr. Karel Urbánek, Ph.D., prim. MUDr. Jan Vachek, MUDr. et Mgr. Jolana Těšínová, Ph.D.

Léčba akutní pooperační bolesti
Autoři: doc. MUDr. Jiří Málek, CSc.

Nové antipsychotikum kariprazin v léčbě schizofrenie
Autoři: prof. MUDr. Cyril Höschl, DrSc., FRCPsych.

Všechny kurzy
Kurzy Doporučená témata Časopisy
Přihlášení
Zapomenuté heslo

Nemáte účet?  Registrujte se

Zapomenuté heslo

Zadejte e-mailovou adresu se kterou jste vytvářel(a) účet, budou Vám na ni zaslány informace k nastavení nového hesla.

Přihlášení

Nemáte účet?  Registrujte se